User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia.

Primary tabs

download
  • Open access
  • PDF
  • 156.78 K
Stilgenbauer, Stephan Aurran Schleinitz, Thérèse Eichhorst, Barbara Lang, Fabian Offner, Fritz Van Den Neste, Eric [UCL] Zenz, Thorsten

To the Editor: Chronic lymphocytic leukemia (CLL) remains incurable for most patients, requiring repeated therapy [1]. The tetraspanin CD37 is predominantly expressed on mature B cells, with low-level expression on T cells, granulocytes, and monocytes, and is widely expressed in mature B-cell malignancies, including CLL [...]

Document type Article de périodique (Journal article) – Lettre à l'éditeur
Access type Accès libre
Publication date 2019
Language Anglais
Journal information "Leukemia" - Vol. 33, no.10, p. 2531-2535 (2019)
Peer reviewed yes
Publisher Nature Publishing Group ((United Kingdom) London)
issn 0887-6924
e-issn 1476-5551
Publication status Publié
Affiliations UCL - SSS/DDUV - Institut de Duve
UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique
UCL - (SLuc) Service d'hématologie
MESH Subject Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized ; Antigens, Neoplasm ; Antineoplastic Agents, Immunological ; Antineoplastic Combined Chemotherapy Protocols ; Female ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell ; Lymphoma, B-Cell ; Male ; Middle Aged ; Tetraspanins
Links
Bibliographic reference Stilgenbauer, Stephan ; Aurran Schleinitz, Thérèse ; Eichhorst, Barbara ; Lang, Fabian ; Offner, Fritz ; et. al. Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia.. In: Leukemia, Vol. 33, no.10, p. 2531-2535 (2019)
Permanent URL http://hdl.handle.net/2078.1/243495